Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis

Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by fibrosis, inflammation and vasculopathy in the skin and internal organs. Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2017-09, Vol.35 Suppl 106 (4), p.208-210
Main Authors: Ichihara, Asako, Jinnin, Masatoshi, Ihn, Hironobu
Format: Article
Language:English
Subjects:
Humans
Interleukin-12 - antagonists & inhibitors
Interleukin-23 - antagonists & inhibitors
Interleukin-23 - blood
Male
Middle Aged
Psoriasis - drug therapy
Psoriasis - immunology
Scleroderma, Systemic - drug therapy
Scleroderma, Systemic - immunology
Skin - drug effects
Skin - pathology
Th17 Cells - physiology
Ustekinumab - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by fibrosis, inflammation and vasculopathy in the skin and internal organs. Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc. We report a case of SSc and psoriasis administered ustekinumab, IL-12/IL-23 inhibitor. In this case, the skin tightening was successfully improved and ustekinumab was more effective, even though oral prednisolone (9-12 mg/day) had some effect on skin tightening and arthralgia. We consider that inhibition of Th17 cytokines may lead to therapeutic efficacy against SSc. Ustekinumab has the potential for a treatment option of SSc.
ISSN:0392-856X